![](/img/cover-not-exists.png)
121TiPKEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)
Cardoso, F, Jia, L, Hirshfield, K, Karantza, VVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz097.013
Date:
May, 2019
File:
PDF, 76 KB
2019